华润博雅生物制药集团股份有限公司（以下简称公司）监事会于2024年8月9 日收到公司监事会主席唐娜女士递交的书面《辞职报告》，唐娜女士因工作调动 申请辞去公司第八届监事会监事、监事会主席职务，辞职后将不再担任公司任何 职务。唐娜女士的离职不会影响公司的正常生产运营。截至本公告披露日，唐娜 女士未持有公司股份。 鉴于唐娜女士的辞职将导致公司监事会人数低于法定最低人数，根据《中华 人民共和国公司法》《深圳证券交易所上市公司自律监管指引第2号——创业板 上市公司规范运作》及《公司章程》等有关规定，唐娜女士在公司召开股东大会 补选产生新任监事前继续履行监事及监事会主席职责。公司将按照有关规定，尽 快完成监事补选工作。 证券代码：300294 证券简称：博雅生物 公告编号：2024-049 华润博雅生物制药集团股份有限公司 关于公司监事会主席辞职的公告 本公司及监事会全体成员保证公告内容真实，准确和完整，没有虚假记载， 误导性陈述或重大遗漏。 唐娜女士在任职期间，始终恪尽职守、勤勉尽责，为促进公司规范运作和健 康发展发挥了重要作用。公司监事会对唐娜女士在任职期间为公司发展做出的努 力和贡献表示衷心感谢！ 特此公告。 华 ...

证券代码：300294 证券简称：博雅生物 公告编号：2024-047 华润博雅生物制药集团股份有限公司 关于签署战略合作框架协议的公告 （一）交易对方：GC 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、华润博雅生物制药集团股份有限公司（以下简称华润博雅生物、公司） 与华润医药集团有限公司（以下简称华润医药）于 2024 年 7 月 17 日和 GC Corp. （以下简称 GC）签署《战略合作框架协议》，此为框架性协议，具体的实施内 容和操作细节将以另行签订的具体项目合作协议为准。如果该框架协议与后续签 署的具体落地协议文件的约定有差异，则以具体落地协议文件的约定为准。 2、合作方华润医药为公司关联方，根据《深圳证券交易所创业板股票上市 规则》（以下简称《股票上市规则》）的有关规定，框架协议涉及的交易事项构 成关联交易，但因本协议为框架性协议，尚未构成关联交易的实质。 3、本次签署的《战略合作框架协议》仅反映协议双方的合作意向或原则， 具体项目的实施情况及进度存在一定的不确定性。协议的签署不会对公司 2024 年度经营业绩产生重大影响，对未来年 ...

Financial Performance - The company's revenue for Q1 2024 was ¥448,452,537.26, a decrease of 44.36% compared to ¥805,928,136.64 in the same period last year[5] - Net profit attributable to shareholders for Q1 2024 was ¥152,024,886.81, down 10.74% from ¥170,317,490.97 in the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥127,306,750.41, a decrease of 7.63% from ¥137,815,331.11 year-on-year[5] - Basic and diluted earnings per share for Q1 2024 were both ¥0.30, a decline of 11.76% from ¥0.34 in the previous year[5] - The net profit for the period is reported at ¥151,760,842.43, compared to ¥174,373,215.65 in the previous period, showing a decrease of about 12.92%[27] - The total comprehensive income amounted to 151,760,842.43, down from 174,373,215.65, indicating a decrease of about 13.0%[28] - Basic and diluted earnings per share were both 0.30, compared to 0.34 in the previous period, reflecting a decline of approximately 11.8%[28] - The company reported a net profit of ¥151,760,842.43 for the current period, down 14.5% from ¥177,373,215.65 in the previous period[39] Cash Flow and Assets - The net cash flow from operating activities was ¥123,871,710.13, down 44.37% from ¥222,678,836.22 in the same quarter last year[5] - Cash flow from operating activities was 410,436,128.44, significantly lower than 782,399,226.54, representing a decrease of about 47.5%[28] - The company's cash and cash equivalents at the end of Q1 2024 amount to ¥1,860,435,345.29, down from ¥1,961,478,737.03 at the beginning of the period, representing a decrease of approximately 5.14%[12] - The net increase in cash and cash equivalents was -105,345,193.69, contrasting with a positive increase of 179,436,811.37 in the previous period[31] - Total assets at the end of Q1 2024 were ¥7,992,850,470.88, an increase of 2.09% from ¥7,828,900,301.89 at the end of the previous year[5] - The total current assets rose to 6,612,770,411.54 from 6,427,633,042.37, indicating an increase of about 2.9%[36] - The total non-current assets decreased to 1,380,080,059.34 from 1,401,267,259.52, reflecting a decline of approximately 1.5%[36] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,406[10] - The largest shareholder, China Resources Pharmaceutical Group, holds 29.28% of shares, totaling 147,640,553 shares[10] - The number of shares held by the top ten shareholders includes significant stakes from institutional investors, with the second-largest shareholder holding 11.31%[10] Operating Costs and Expenses - The company reported a significant decrease in operating costs, which were ¥144,457,836.40, down 65.93% from ¥424,061,104.31 year-on-year[7] - Total operating costs for the current period were ¥301,267,242.96, down 52.5% from ¥634,659,929.03 in the previous period[39] - Research and development expenses increased by 90.36% to ¥19,006,039.85 compared to ¥9,984,394.66 in the same period last year[7] - Research and development expenses increased to ¥19,006,039.85, up 90.5% from ¥9,984,394.66 in the previous period[39] Liabilities and Equity - Total liabilities amounted to ¥520,264,129.08, an increase of 2.3% from ¥508,074,802.52 in the previous period[39] - Shareholders' equity attributable to the parent company was ¥7,471,775,464.59, up 2.08% from ¥7,319,750,577.78 at the end of last year[5] - Total equity attributable to shareholders reached ¥7,471,775,464.59, up 2.1% from ¥7,319,750,577.78 in the previous period[39] Non-Recurring Gains and Losses - The company has no significant changes in non-recurring gains and losses that would affect its financial reporting[19] - The company has not reclassified any non-recurring gains and losses as regular gains and losses[19]

华润博雅生物制药集团股份有限公司 经理层成员绩效管理办法 （2024 年 4 月制定） 第一章 总 则 为深入贯彻习近平新时代中国特色社会主义思想，深化国有企业改革， 完善国有企业市场化经营机制，优化公司治理结构，进一步规范经理层成员经营业绩 考核，促进组织和个人业绩达成，结合华润博雅生物制药集团股份有限公司（以下简 称"公司"）实际，特制定本办法。 第二条 本办法适用于公司经理层成员，包括总裁、副总裁，以及公司章程规定 的其他高级管理人员。 经理层成员绩效管理办法 第三条 管理原则 一、目标导向。经理层成员经营业绩考核遵循目标导向原则，围绕公司战略并逐 级分解，确保目标一致，促进公司战略目标的达成。 二、建立健全考核体系。坚持"定性"与"定量"相结合的原则，制定具体的、 可衡量的经营业绩考核指标，结合指标完成情况，建立全面、科学的考核体系。 三、强化考核结果运用。秉承和落实"业绩文化"，强化考核结果运用，经理层 成员经营业绩考核结果与薪酬激励、干部管理强关联。 第二章 管理职责 第四条 管理职责 一、董事会是经理层成员经营业绩考核的决策主体，履行以下职责： （一）审批经理层成员绩效管理办法。 第 1 页 共 ...

2023 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：300294 证券简称：博雅生物 公告编号：2024-038 华润博雅生物制药集团股份有限公司 特别提示： 1、公司本次实施的利润分配方案为：以股份总数504,248,738股为基数，向 全体股东每10股派发现金红利3.000000元（含税）。公司本次现金分红的总金额 = 实 际 参 与 分 配 的 股 本 ×分配比例 =504,248,738 股 ×3.000000 元 ÷10 股 =151,274,621.40元。自分配方案披露至实施期间公司股本总额未发生变化，若发 生变化公司将按照现金分红总额不变的原则对分配比例进行调整。 2、本次权益分派方案实施后，按公司总股本折算每股现金分红=本次实际现 金分红总额/公司总股本=151,274,621.40/504,248,738=0.300000元。因此，在保证 本次权益分派方案不变的前提下，公司2023年年度权益分派实施后的除权除息价 格按照上述原则及计算方式执行，即本次权益分派实施后的除权除息价格=除权 除息日前收盘价-按总股 ...

中信证券股份有限公司关于 华润博雅生物制药集团股份有限公司 向特定对象发行股票并在创业板上市 之持续督导保荐总结报告书 | | | 一、发行人基本情况 | 项目 | 内容 | | --- | --- | | 发行人名称 | 华润博雅生物制药集团股份有限公司 | | 证券代码 | 300294.SZ | | 注册资本 | 504,248,738元 | | 注册地址 | 江西省抚州市高新技术产业园区惠泉路333号 | | 主要办公地址 | 江西省抚州市高新技术产业园区惠泉路333号 | | 法定代表人 | 梁小明 | | 董事会秘书 | 梁化成 | | 联系电话 | 0794-8264398 | | 本次证券发行类型 | 向特定对象发行股票 | | 本次证券上市时间 | 2021年11月25日 | | 本次证券上市地点 | 深圳证券交易所 | 二、本次发行情况概述 经中国证监会《关于同意博雅生物制药集团股份有限公司向特定对象发行股 票注册的批复》（证监许可﹝2021﹞3340 号）核准，博雅生物制药集团股份有限 公司（以下简称"公司"）以 31.37 元/股向特定对象华润医药控股有限公司发行股 份 78,308, ...

中信证券股份有限公司 关于华润博雅生物制药集团股份有限公司 2023 年年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：博雅生物 | | --- | --- | | 保荐代表人姓名：赵洞天 | 联系电话：010-60838275 | | 保荐代表人姓名：黄江宁 | 联系电话：010-60836569 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次 | 次 0 | | 数 | | | 2．督导公司建立健全并有效执行规章制 | | | 度的情况 | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的 | 是 | | 制度、募集资金管理制度、内控制度、内 | | | 部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是，根据 2023 年度内控自我评价报告、 | | | 2023 年度内部控制审计报告，发行人 | | | 有效执行了相关规章制度 | | 3.募集资金监督 ...

中信证券股份有限公司 关于华润博雅生物制药集团股份有限公司 2023 年度持续督导定期现场检查报告 | 保荐人名称：中信证券股份有限公司 被保荐公司简称：博雅生物 | | --- | | （以下简称"中信证券"或"保荐人"） | | 保荐代表人姓名：赵洞天 联系电话：010-60838275 | | 保荐代表人姓名：黄江宁 联系电话：010-60836569 | | 现场检查人员姓名：赵洞天、朱印 | | 现场检查对应期间：2023 年 1 月 1 日-2023 年 12 月 31 日 | | 年 月 日至 年 月 日 现场检查时间：2024 3 19 2024 3 28 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段： | | 查阅了上市公司最新章程、三会议事规则及会议材料，取得上市公司董事、监事、 | | 高级管理人员名单及其变化情况，取得上市公司关联方清单，查阅关于公司控股 | | 股东、实际控制人、董事、监事、高级管理人员的信息披露文件及相关变更决策 | | 文件，查看上市公司生产经营场所，对上市公司董事、高级管理人员进行访谈。 | | 3.三会会 ...

Board and Management Changes - The company held the 29th meeting of the 7th Board of Directors on March 4, 2024, approving the election of candidates for the 8th Board of Directors, including Mr. Qiu Kai and Mr. Liang Xiaoming as non-independent directors[1]. - The term of the independent directors Mr. Zhang Weidong, Mr. Zhao Li, and Mr. Huang Huasheng will end on February 2, 2027[2]. - The company elected Mr. Rao Zhen as the employee representative supervisor during the 6th meeting of the 6th Employee Representative Assembly on March 11, 2024[1]. - The 8th Board of Directors held its first meeting on March 21, 2024, where it approved the election of the chairman and the appointment of senior management personnel[1]. - The company has experienced changes in its board and management personnel, with several new appointments effective from October 25, 2023[5]. - The new board members include Mr. Qiu Kai as Chairman and Mr. Liang Xiaoming as President, both with extensive backgrounds in the pharmaceutical industry[6]. - The company is expanding its governance structure with the election of independent directors and supervisors to enhance oversight and compliance[2]. - The company’s leadership changes are aimed at driving future growth and innovation in the pharmaceutical sector[6]. Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.2 billion for the fiscal year 2023, representing a year-on-year growth of 15%[146]. - The company's operating revenue for 2023 was ¥2,651,979,506.66, a decrease of 3.87% compared to ¥2,758,701,315.10 in 2022[154]. - The net profit attributable to shareholders for 2023 was ¥237,465,593.87, down 45.06% from ¥432,197,553.97 in 2022[154]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥143,075,746.77, a decline of 63.51% compared to ¥392,124,538.69 in 2022[154]. - The gross margin for the year was reported at 45%, a slight decrease from 48% in the previous year, attributed to increased raw material costs[146]. - The company reported a loss of CNY 3,894.56 million from the transfer of 89.681% equity of Guizhou Tianan Pharmaceutical Co., Ltd.[126]. - The company reported a net profit loss in the fourth quarter primarily due to a goodwill impairment provision of CNY 298.41 million related to the acquisition of Nanjing Xinbai Pharmaceutical Co., Ltd.[186]. Compliance and Governance - The company is committed to maintaining compliance with the regulations regarding independent directors, ensuring governance best practices[2]. - The company has received regulatory measures from the China Securities Regulatory Commission for information disclosure violations, which have been recorded in the integrity archives[15]. - The company is committed to ensuring the legality of economic contracts and major investment decisions, with a 100% legal review of important regulations and contracts[30]. - The internal control system has been strengthened, with timely reviews and updates to internal control procedures across various business areas, ensuring effective implementation[29]. - The company has reported no significant internal control deficiencies during the reporting period, indicating a robust internal control environment[33]. - The company has no violations or rectification situations during the reporting period[117]. - The company maintains a good integrity status for itself and its controlling shareholders[118]. Marketing and Strategic Focus - The company aims to enhance plasma station management capabilities, focusing on cost control and establishing benchmark stations to promote internal growth[20]. - The company plans to implement marketing reforms by adopting a refined招商 business model and building its own sales team to improve channel control and brand influence[22]. - The company is focused on increasing plasma collection volume by enhancing brand marketing and emotional engagement with donors[20]. - The company has a strategic focus on leveraging cornerstone products to drive sales and improve marketing effectiveness through targeted strategies[22]. - The company is accelerating marketing transformation and restructuring its marketing model to enhance management capabilities and focus on terminal hospital development and pure sales management[23]. - The company aims to increase market share by implementing targeted marketing strategies for core products such as pituitary posterior lobe, oxytocin, and bone peptide tablets, with a focus on developing blank areas[23]. Research and Development - The company is enhancing its innovative R&D capabilities by introducing or developing new products and activating the commercial value of dormant varieties to accelerate project sales[25]. - The company acknowledges that the development and launch of new blood products involve a lengthy and high-risk process, requiring significant resources and funding[24]. - Research and development expenses increased by 25% to RMB 150 million, reflecting the company's commitment to innovation[146]. - The company has established strategic partnerships with two leading research institutions to accelerate the development of new therapies[146]. - The company is actively developing new products, including a novel immunoglobulin therapy expected to enter clinical trials in Q2 2024[146]. Environmental Compliance - Huaren Boya Bio's existing projects have passed environmental impact assessments and obtained valid discharge permits[41]. - The company reported a COD level of 81.220 mg/L, which is below the national standard of 220 mg/L, with a total discharge of 4.885 tons[46]. - New Bai Pharmaceutical's gas emissions for non-methane total hydrocarbons were recorded at 0.49 mg/m³, significantly below the standard of 4 mg/m³[46]. - The company has received environmental impact report approvals for multiple construction projects, ensuring compliance with environmental regulations[41]. - The company has implemented pollution prevention measures in accordance with the environmental impact reports for its construction projects[40]. - The company has established a comprehensive pollution prevention and control system, ensuring compliance with environmental regulations[58]. - The company has implemented an automatic monitoring system for VOCs, which will enable real-time monitoring of volatile organic compounds after installation[63]. Social Responsibility - The company has invested a total of 2.62 million yuan in poverty alleviation efforts, focusing on improving educational resources in impoverished areas[82]. - The company allocated 150,000 yuan towards healthcare resources in impoverished regions as part of its poverty alleviation initiatives[85]. - The company has implemented a comprehensive employment strategy that promotes equal opportunities and adheres to labor laws, ensuring fair treatment of all employees[73]. Related Party Transactions - The total amount of related party transactions with China Resources Pharmaceutical Holdings and its affiliates reached CNY 29,636.92 million, accounting for 9.91% of similar transactions[121]. - The company sold 75% equity of Guangdong Fuda Pharmaceutical Co., Ltd. for CNY 36,476.42 million, resulting in a profit of CNY 3,427.62 million[123]. - The company has approved a transaction limit of CNY 31,320.00 million for related party transactions, which was not exceeded[121]. - The company reported a significant increase in user data, with a year-over-year growth of 29.34% in purchasing goods from related parties[121]. - The company has no significant related party transactions or loans during the reporting period[158][159]. Market Outlook - Looking ahead, the company projects a revenue growth of 10% for 2024, targeting RMB 1.32 billion in total revenue[146]. - The blood products industry is expected to maintain a stable growth trend due to the increasing demand for products like immunoglobulin and the stable pricing system established in the Beijing-Tianjin-Hebei region[200]. - By 2027, the Chinese blood products market is expected to reach CNY 78 billion, with a compound annual growth rate (CAGR) of 11.6% from 2022 to 2027[196]. - The number of newly operational plasma stations in China in 2023 was 33, indicating an acceleration in industry consolidation[196].

证券代码：300294 证券简称：博雅生物 公告编号：2023-057 华润博雅生物制药集团股份有限公司 关于单采血浆站取得《营业执照》的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，华润博雅生物制药集团股份有限公司（以下简称公司）下属单采血浆 站"泰和博雅单采血浆有限公司"（以下简称泰和浆站）和"乐平市博雅单采血 浆有限公司"（以下简称乐平浆站）取得市场监督管理局颁发的《营业执照》， 其相关信息如下： 泰和浆站、乐平浆站均为公司全资子公司，上述浆站将按照相关法律法规及 标准要求进行建设，建成后根据《单采血浆站管理办法》等有关要求提交执业申 请，经验收合格后开展采浆工作。 公司将根据上述单采血浆站建设的进展情况及时进行信息披露。 特此公告。 华润博雅生物制药集团股份有限公司董事会 2023 年 11 月 20 日 一、泰和博雅单采血浆有限公司《营业执照》信息 二、乐平市博雅单采血浆有限公司《营业执照》信息 名 称：泰和博雅单采血浆有限公司 统一社会信用代码：91360826MAD598XD2P 类 型：有限责任公司(非自然人投资或控股的法人独资) 住 ...